Fatty acid sustained release from contact lenses

The problem of wearing discomfort with existing contact lenses is solved by releasing fatty acids using glycerol phospholipids in contact lenses, achieving longer-term comfortable wearing and reducing glasses perception events.

CN118922747AActive Publication Date: 2024-11-08COOPERVISION INT LTD
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
CN202380029944.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-09-27
Filing Date
2023-09-25
Publication Date
2024-11-08
Estimated Expiration
2043-09-25

AI Technical Summary

Technical Problem

Existing contact lenses cause discomfort during wear, and some materials cannot continuously release fatty acids, thereby reducing the comfort and shortening the wear time.

Method used

Hydrogel contact lenses containing glycerol phospholipids with C12-C26 acyl group at the sn-2 position were used to perform enzymatic reactions using sPLA2 enzyme in human tears to continuously release fatty acids such as oleic acid to enhance comfort and extend wear time.

Benefits of technology

By continuously releasing fatty acids, the comfort of contact lenses is significantly improved, and the wear time is increased in contact lens wearers, reducing glasses perception events.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922747A_ABST
    Figure CN118922747A_ABST
Patent Text Reader

Abstract

Fatty acid releasing contact lenses and methods of making the same are described. The fatty acid-releasing contact lens comprises glyceryl phospholipids loaded to a polymer lens body, and continuously releases C12-C26 fatty acids after 1 hour in a release medium comprising an sPLA2 enzyme solution. The fatty acid releasing contact lenses may be comfortably worn by a contact lens wearer and may increase the duration of comfortable eyewear wearing time and / or reduce eyewear perceiving events in the contact lens wearer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The field of the invention relates to contact lenses, and in particular, to contact lenses that are more comfortable for contact lens wearers. Background Art

[0002] It is estimated that 50% of all contact lens wearers experience discomfort when wearing their lenses, and approximately 25% of these contact lens wearers permanently stop wearing their lenses. Lens-perceived sensation is the leading cause of contact lens dissatisfaction among contact lens wearers. Despite advances in contact lens materials, there remains a need for improved contact lenses that can be comfortably worn by contact lens wearers who otherwise experience lens-perceived sensation when wearing currently commercially available contact lenses.

[0003] Fatty acids are known to act as comfort agents that provide lubrication and relieve discomfort when administered to the eye. Fatty acids acting as comfort agents can be released from contact lenses during wear in an amount sufficient to desensitize the eye and thereby relieve discomfort (U.S. Patent Application Publication No. 20220187620). However, some contact lens materials are unable to maintain fatty acid release throughout the day.

[0004] It would be desirable to obtain a sustained rate of fatty acid release from a contact lens throughout the duration of lens wear, thereby increasing the duration in which a contact lens wearer can comfortably wear the contact lens.Alternatively or additionally, it would be desirable to provide an improved contact lens that can be worn by a contact lens wearer. Summary of the invention

[0005] A feature of the present invention is to provide a hydrogel contact lens that releases fatty acids, particularly C 12 -C 26 Fatty acids, such as oleic acid.

[0006] Another feature of the present invention is to provide a contact lens that can be comfortably worn by a contact lens wearer.

[0007] Another feature of the present invention is to increase the duration of comfortable lens wear time and / or reduce lens perception events in contact lens wearers.

[0008] Other features and advantages of the present invention will be described in part in the following description, and in part will be known from the description, or can be learned by practicing the present invention. The objectives and other advantages of the present invention will be realized and obtained by means of the components and combinations particularly pointed out in this description and the appended claims.

[0009] To achieve these and other advantages and in accordance with the purposes of the present invention, as embodied and broadly described herein, the present invention relates in part to a hydrogel contact lens comprising a polymer lens body loaded with a phospholipid, wherein the phospholipid is a12 -C 26 A glycerophospholipid having an acyl group at the sn-2 position. The phospholipid is advantageously susceptible to digestion by secretory phospholipase 2-acyl hydrolase (sPLA2) enzymes found in human tears (particularly secretory phospholipase 2-acyl hydrolase of group IIA (sPLA2-IIA)). The phospholipid present in the contact lens body is advantageously a glycerophospholipid susceptible to digestion by sPLA2 enzymes found in human tears (particularly sPLA2-IIA) when present in a hydrogel contact lens, particularly a silicone hydrogel contact lens, such as a polymer lens body of a stenfilcon A contact lens. After immersing the same stenfilcon A contact lens loaded with the glycerophospholipids in each release medium for 4 hours at 35°C, C derived from the digestion of the acyl group at the sn-2 position is released from the stenfilcon A lens loaded with at least 200 μg of glycerophospholipid into the artificial tear (ATF) release medium containing the sPLA2 enzyme. 12 -C 26 The amount of fatty acids released into an otherwise identical control ATF release medium lacking the phospholipase A2 enzyme is C 12 -C 26 At least 3 times the amount of fatty acids, including C 12 -C 26Glycerophospholipids with acyl groups at the sn-2 position may be considered susceptible to digestion by the sPLA2 enzyme. An exemplary ATF release medium containing the sPLA2 enzyme may be a release medium defined in Table 1 below that additionally contains 50 ppm of recombinant human sPLA2-IIA and a control release medium lacking the phospholipase A2 enzyme may be an otherwise identical ATF release medium lacking the phospholipase A2 enzyme. Alternatively, the release medium containing the sPLA2 enzyme may be a reflex tear solution and the control release medium may be ATF. For the avoidance of doubt, although the determination of whether a glycerophospholipid is susceptible to digestion by the sPLA2 enzyme may be performed by loading the glycerophospholipid into a Stanfecon A lens, the contact lenses of the present invention (including contact lenses comprising glycerophospholipids that have been determined to be susceptible to digestion by the sPLA2 enzyme) need not be Stanfecon A lenses. In all aspects of the present invention, the contact lenses in which the glycerophospholipids are susceptible to digestion by the sPLA2 enzyme may be any contact lenses described herein. An example of a phospholipid that is not easily digested by the sPLA2 enzyme found in human tears when present in a silicone hydrogel contact lens body is, for example, 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) or 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) from the phosphatidylcholine family. The phospholipid present in the contact lens body is advantageously not DMPC. The phospholipid present in the contact lens body may not be DMPC or DOPC. The phospholipid present in the contact lens body may not be glycerophosphocholine or may not be phosphocholine. The phospholipid may be an anionic glycerophospholipid or a zwitterionic glycerophospholipid. Anionic glycerophospholipids include phospholipids attached to the phospholipid head group (i.e., at the R 3 The phospholipid may be of formula (I):

[0010]

[0011] Where X is –O– or –O(CO)–, R 1 and R 2 Each independently is C 11-25 Alkyl, R 3 is selected from hydrogen; C 1-10 polyols (eg, glycerol or inositol); ethanolamine (-CH2CH2NH2); and serine (-CH2CH(NH2)COOH), and salts of phospholipids of formula (I) (eg, wherein R 3 Negatively charged or deprotonated anionic groups (e.g. -CH2CH(NH2)COO - )). Preferably, R 3 is not choline, that is, the glycerophospholipid is not 1,2-dioleoyl-sn-glycero-3-phosphocholine. It has been found that the hydrogel contact lens of the present invention releases C 12-C 26 Fatty acids, thereby enhancing the comfort of the contact lens in a lens wearer and / or increasing the duration of comfortable contact lens wearing time in a contact lens wearer.

[0012] In one embodiment, after the hydrogel contact lens is immersed in an ATF release medium containing a 50 ppm sPLA2-IIA enzyme solution in phosphate buffered saline (PBS) at 35° C. for 1 hour, the hydrogel contact lens can release 0.01 μg to 50 μg, 0.05 μg to 40 μg, and particularly 0.1 μg to 25 μg C 12 -C 26 fatty acid.

[0013] Furthermore, the present invention relates to a method for making the hydrogel contact lens of the present invention. The method comprises the steps of: a) polymerizing a polymerizable composition (as described herein) in a contact lens casting mold to obtain a polymer lens body, b) removing the polymer lens body from the contact lens casting mold, c) heating the polymer lens body in a solution containing a mixture of C 12 -C 26 The invention relates to a method for preparing a polymer lens body having a hydrogel contact lens and a phospholipid containing acyl groups in an organic solvent, d) hydrating the polymer lens body in a hydrating liquid to obtain a hydrogel contact lens, e) sealing the hydrogel contact lens in a package with a packaging solution, and f) treating the package by evaporation. The hydration step d) may occur before the extraction step c) in which the phospholipids are loaded into the polymer lens body. If the hydration step d) occurs before the extraction step c) in which the phospholipids are loaded into the polymer lens body, an additional hydration step may be performed after step c).

[0014] In addition, the present invention relates to a method of providing a symptomatic contact lens wearer with a polymer lens body loaded with C 12 -C 26 Release of glycerophospholipids with acyl groups at the sn-2 position 12 -C 26 Method for correcting vision of symptomatic contact lens wearers by using hydrogel contact lenses containing fatty acids, particularly hydrogel contact lenses releasing oleic acid. Advantageously, compared to hydrogel contact lenses not containing C 12 -C 26The fatty acid releasing hydrogel contact lens increases the duration of comfortable contact lens wearing time and / or reduces lens perception events in the symptomatic contact lens wearer. The phospholipid is advantageously a glycerophospholipid that is easily digested by the sPLA2 enzyme (especially sPLA2-IIA) found in human tears when present in the polymer lens body, such as a glycerophospholipid of formula (I). As used herein, a "symptomatic contact lens wearer" is a lens wearer classified as symptomatic using the CLDEQ-8 described by Chalmers et al. (See Chalmers et al., Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and opinion of contact lens performance. Optom Vis Sci 2012; 89(10): 1435-1442.).

[0015] In addition, the present invention relates to a contact lens wearer using a contact lens containing C 12 -C 26 Release of glycerophospholipids with acyl groups at the sn-2 position 12 -C 26 Compared with hydrogel contact lenses containing no fatty acids, 12 -C 26 Control lenses of glycerophospholipids having an acyl group at the sn-2 position increase the duration of comfortable contact lens wear time and / or reduce lens perception events.

[0016] In addition, the present invention relates to a method comprising 12 -C 26 Use of a glycerophospholipid having an acyl group at the sn-2 position for enhancing the comfort of a contact lens, wherein the glycerophospholipid is associated with the polymer lens body of the contact lens.

[0017] In addition, the present invention relates to a hydrogel composition for reducing the perceived feel of a contact lens in a contact lens wearer, thereby enhancing the comfort of the contact lens in the contact lens wearer and / or increasing the duration of comfortable contact lens wearing time in the contact lens wearer, the composition comprising (a) a polymer lens body that is a reaction product of a polymerizable composition, loaded with (b) an amount of a polymer comprising C 12 -C 26 Glycerophospholipids with the acyl group at the sn-2 position.

[0018] In all aspects of the present invention, comprising C 12 -C 26The glycerophospholipids having an acyl group at the sn-2 position are advantageously susceptible to digestion by sPLA2 enzymes (especially group IIA sPLA2) found in human tears when the glycerophospholipids are present in the polymer lens body of a hydrogel contact lens (especially a silicone hydrogel contact lens). 12 -C 26 The contact lens of the glycerophospholipid having an acyl group at the sn-2 position is characterized in that: (a) when the contact lens is immersed in human reflex tears at 35°C for 4 hours, 3 times the amount of C 2+ is detected in the reflex tears compared to when the lens is immersed in ATF release medium lacking phospholipase A2 enzyme at 35°C for 4 hours 12 -C 26 and / or (b) when the contact lens is immersed in ATF release medium containing 50 ppm recombinant human group IIa phospholipase A2 for 4 hours at 35°C, 3 times the amount of C is detected in the reflex tear fluid when the lens is immersed in an equivalent ATF release medium lacking the phospholipase A2 enzyme for 4 hours at 35°C. 12 -C 26 Fatty acid degradation products. The phospholipids are usually glycerophospholipids, such as glycerophospholipids of formula (I):

[0019]

[0020] Where X is –O– or –O(CO)–, R 1 and R 2 Each independently is C 11-25 Alkyl, R 3 The group is selected from hydrogen, C 1-10 polyols, ethanolamine (-CH2CH2NH2) and serine (-CH2CH(NH2)COOH), and salts thereof (e.g., wherein R 2 Negative charge, or the ethanolamine is protonated to -CH2CH2NH3 + ).

[0021] Other aspects of the invention are provided in the following numbered clauses:

[0022] 1. An unworn hydrogel contact lens sealed in a package, the contact lens comprising a polymer lens body loaded with C 12 -C 26 Glycerophospholipids with the acyl group at the sn-2 position.

[0023] 2. A contact lens according to clause 1, wherein the glycerophospholipid when present in the polymer lens body is susceptible to digestion by the secretory phospholipase A2 (sPLA2) enzyme found in human tears.

[0024] 3. A contact lens according to clause 1 or 2, wherein the glycerophospholipid is of formula (I):

[0025]

[0026] Where X is –O– or –O(CO)–, R 1 and R 2 Each independently is C 11-25 Alkyl and R 3 The group is selected from hydrogen, C 1-10 Polyols, ethanolamine and serine, and salts thereof.

[0027] 4. A contact lens as in item 3, wherein R 1 and R 2 Each independently is C 13-21 alkyl.

[0028] 5. A contact lens according to any preceding clause, wherein the glycerophospholipid is phosphatidylserine, phosphatidylethanolamine or phosphatidylglycerol.

[0029] 6. The contact lens of clause 5, wherein the glycerophospholipid is phosphatidylglycerol, in particular 1,2-dioleoylphosphatidylglycerol, 1-palmitoyl-2-oleoylphosphatidylglycerol, 1-stearoyl-2-oleoyl or 1,2-di(docosahexaenoyl)phosphatidylglycerol.

[0030] 7. The contact lens of any one of clauses 1 to 4, wherein the glycerophospholipid is not dimyristoylphosphatidylcholine (DMPC).

[0031] 8. The contact lens of any one of clauses 1 to 4, wherein the glycerophospholipid is not phosphatidylcholine.

[0032] 9. The contact lens of any one of clauses 1 to 8, wherein the contact lens is a silicone hydrogel contact lens.

[0033] 10. The contact lens of any one of clauses 1 to 9, wherein the hydrogel is neutral or cationic.

[0034] 11. The contact lens of any one of clauses 1 to 10, wherein the polymer lens body is the reaction product of a polymerizable composition comprising at least one hydrophilic monomer comprising a vinyl group.

[0035] 12. The contact lens of any one of clauses 1 to 11, wherein the polymer lens body is a first siloxane comprising a structure represented by formula (II),

[0036]

[0037] and a polymerizable composition of a second siloxane having a structure represented by formula (III),

[0038]

[0039] 13. A contact lens as in any preceding clause, wherein the hydrogel contact lens releases C when contacted with a solution comprising sPLA2-IIA. 12 -C 26 Fatty acids and their salts, of which C 12 -C 26 Fatty acids are the digestion products of the glycerophospholipids.

[0040] 14. The contact lens of any preceding clause, wherein the polymer lens body is loaded with glycerophospholipid in an amount of 1 μg to 1000 μg, preferably 25 μg to 300 μg.

[0041] 15. The contact lens of any preceding clause, wherein when the contact lens is immersed in a release medium comprising artificial tears containing 50 ppm PLA2-IIA at 35°C, the contact lens continuously releases at least 0.05 μg / hr C 12 -C 26 Fatty acids, especially at least 0.1 μg / hr C 12 -C 26 Fatty acids or 1μg / hr C 12 -C 26 Fatty acid, for at least 4 hours, such as at least 8 hours, optionally at least 10 hours.

[0042] 17. A contact lens according to any preceding clause having an equilibrium water content of at least 40%.

[0043] 18. A contact lens according to any preceding clause, wherein the packaging comprises:

[0044] (a) a base member having a cavity for holding a packaging solution; and

[0045] (b) A cover that forms a fluid-tight seal with the base member.

[0046] 19. A method of making a hydrogel contact lens as in any preceding clause, the method comprising: a) polymerizing a polymerizable composition in a contact lens casting mold to obtain a polymer lens body, b) removing the polymer lens body from the contact lens casting mold, c) depositing the polymer lens body in a 12 -C 26The invention relates to a method for preparing a hydrogel contact lens comprising: extracting the acyl group in an organic solvent of the glycerophospholipid at the sn-2 position, d) hydrating the polymer lens body in a hydrating liquid to obtain the hydrogel contact lens, e) sealing the hydrogel contact lens in a package with a packaging solution, and optionally, f) steam-treating the package.

[0047] 20. A method for correcting vision in a symptomatic contact lens wearer, the method comprising wearing a hydrogel contact lens according to any one of clauses 1 to 18 by the symptomatic contact lens wearer.

[0048] 21. The method of clause 20, wherein the symptomatic contact lens wearer has an increased duration of comfortable contact lens wear time compared to a control lens.

[0049] 22. The method of clause 20 or clause 21, wherein the symptomatic contact lens wearer has reduced lens perception and / or fewer "lens perception events" during the day compared to a control lens.

[0050] 23. A quantity containing C 12 -C 26 Use of a glycerophospholipid having an acyl group at the sn-2 position for enhancing the comfort of a contact lens, wherein the glycerophospholipid is associated with the polymer lens body of the contact lens.

[0051] 24. The use according to clause 23, wherein the contact lens is a hydrogel contact lens according to any one of clauses 1 to 16.

[0052] 25. The use of clause 23 or clause 24, wherein the sensation perceived by the lens in the contact lens wearer is reduced, thereby enhancing the comfort of the contact lens in the symptomatic contact lens wearer and / or increasing the duration of comfortable contact lens wearing time in the symptomatic contact lens wearer.

[0053] 26. A hydrogel composition for reducing lens perceived feel in a contact lens wearer, thereby enhancing the comfort of the contact lens in the contact lens wearer and / or increasing the duration of comfortable contact lens wearing time in the contact lens wearer, the composition comprising (a) a polymer lens body that is a reaction product of a polymerizable composition, loaded with (b) an amount of a polymer comprising C 12 -C 26 Glycerophospholipids with the acyl group at the sn-2 position.

[0054] 27. A composition for use according to clause 26, wherein the composition is in the form of a contact lens according to any one of clauses 1 to 18. BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Figure 1Depicts enzymatic hydrolysis of dioleylphosphatidylglycerol (DOPG) by PLA2 at the sn-2 ester bond to produce oleic acid and lysophosphatidylglycerol (LOPG).

[0056] Figure 2 The oleic acid release profile of 5 mg / mL DOPG loaded silicone hydrogel contact lens (Lens A) in ATF with 50 ppm PLA2 enzyme solution is depicted.

[0057] Figure 3 The oleic acid release profile of a 3 mg / mL DOPG-loaded silicone hydrogel contact lens (Lens B) in ATF with 50 ppm sPLA2 enzyme solution is depicted. DETAILED DESCRIPTION

[0058] This article describes a method for sustained release of C during wear. 12 -C 26 The hydrogel contact lens of fatty acid and the method for making the same. The contact lens may be referred to herein as releasing C 12 -C 26 Fatty acid contact lenses. 12 -C 26 The fatty acids are released from the lens during wear in an amount that enhances the comfort of contact lens wear in the contact lens wearer and can increase the duration in which the contact lens wearer can comfortably wear the contact lens. 12 -C 26 Fatty acid-containing spectacles may increase the day-to-day comfort of spectacles wear in symptomatic patients. 12 -C 26 The fatty acid may be a TRPV1 antagonist, such as oleic acid.

[0059] The present invention advantageously provides C from hydrogel contact lenses 12 -C 26 Sustained release of fatty acids, wherein glycerophospholipids (e.g., oleic acid-containing glycerophospholipids) associated with the hydrogel contact lens are broken down to release C 12 -C 26 Fatty acids, especially oleic acid. For effective C 12 -C 26 Fatty acid release rate, the C 12 -C 26 The fatty acid group must occupy the sn-2 (middle) position in the glycerophospholipid structure. 12 -C 26The fatty alcohol- or fatty acid group may occupy the sn-1 (terminal) position in the glycerophospholipid structure. The sn-1 fatty acid may be an alternative fatty acid to the fatty acid in the sn-2 position, i.e. a fatty acid with a different number of carbon atoms. For example, the fatty acid in the sn-2 position may be oleic acid or docosahexaenoic acid and the fatty acid in the sn-1 position may be a fatty acid other than oleic acid or docosahexaenoic acid. In one example, the glycerophospholipid is a 2-oleoylglycerophospholipid, in particular a 2-oleoylphosphatidylglycerol, such as 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG). In another example, the glycerophospholipid is 2-docosahexaenoylphosphatidylglycerol, such as 1,2-bis(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DHA-PG). In the example of DOPG, oleic acid is a fatty acid at the sn-1 and sn-2 positions of phosphatidylglycerol. Figure 1 As shown in , when DOPG-loaded lenses are placed on the eye, DOPG is degraded by the tear enzyme sPLA2-IIA.

[0060] Contains C at the sn-2 position 12 -C 26Acyl glycerophospholipids can be degraded by secretory phospholipase A2 (sPLA2-IIA) enzymes of the IIA group found in human tears. The glycerophospholipids can be, for example, phosphatidic acid, phosphatidylserine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylglycerol or diphosphatidylglycerol. Preferably, the glycerophospholipid is not phosphocholine. It has been found that phosphocholine is less susceptible to degradation by the sPLA2-IIA enzymes of the IIA group found in human tears than other glycerophospholipids. Advantageously, the glycerophospholipid is selected from phosphatidylserine, phosphatidylethanolamine, phosphatidylinositol and phosphatidylglycerol, especially phosphatidylethanolamine or phosphatidylglycerol. The pKa of the amino group of phosphatidylethanolamine (PE) or phosphatidylserine (PS) is preferably in the range of 8 to 10, preferably in the range of 8.5 to 9.8. Additional information on the activity of sPLA2 enzymes can be found in Chem Rev. 2011 Oct 12; 111(10):6130–6185, “Phospholipase A2 Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention,” Dennis et al.

[0061] Regarding “readily digestible,” sPLA2 present in human tears will hydrolyze the acyl group at the sn2 position of glycerophospholipids, thereby generating free fatty acids and lysophospholipids.

[0062] The glycerophospholipids can be digested by human tears. The glycerophospholipids can be digested by sPLA2 present at least in human tears.

[0063] C at the sn-2 position 12 -C 26 The fatty acids are advantageously released and eluted from the lenses, while the remainder of the glycerophospholipids remain within the lenses. 12 -C 26 In addition to the diffusion rate of fatty acids themselves, the C 12 -C 26 The release rate of the fatty acid can be based on the kinetics of the enzymatic reaction of the phospholipid. In one embodiment, the hydrogel contact lens comprises a polymer lens body loaded with 2-oleoyl glycerophospholipid of formula (Ia):

[0064]

[0065] Where X is –O– or –O(CO)–, R 1 C 11-25 Alkyl, R 3 The group is selected from hydrogen, C 1-10 polyols, ethanolamine (-CH2CH2NH2) and serine (-CH2CH(NH2)COOH), and salts thereof (e.g., wherein R 3 Negative charge, or the ethanol case is protonated to -CH2CH2NH3 + ). 3 Advantageously, it is selected from -CH2CH2NH2, -CH2CH(NH2)COOH and -CH2CH(OH)CH2OH, in particular -CH2CH(OH)CH2OH. 1 It may be selected, for example, from oleoyl, myristoyl, pentadecanoyl, palmitoyl or stearoyl.

[0066] The release C 12 -C 26 The fatty acid contact lens comprises a polymer lens body loaded with an amount of C 12 -C 26 A glycerophospholipid having an acyl group at the sn-2 position, which continuously releases C from the lens when in contact with a tear solution comprising sPLA2-IIA 12 -C 26 The tear solution may be human reflex tears or an in vitro release medium comprising ATF containing a Group IIA sPLA2 enzyme solution at a concentration of, for example, 50 ppm.

[0067] As an option, one or more glycerophospholipids as described herein may be present in the C-releasing 12 -C 26 fatty acids in contact lenses (e.g., two different, three different, or more glycerophospholipids as described herein).

[0068] As an example, the contact lens is a non-silicone hydrogel that is free of or substantially free of silicon-containing components, which is a reaction product of a polymerizable composition of a non-silicone hydrogel. A hydrogel containing less than 3 wt%, especially less than 2 wt%, preferably less than 1 wt% of units derived from a silicon-containing monomer or macromer is a non-silicone hydrogel that is substantially free of silicon-containing components. Non-silicone hydrogel contact lenses are typically formed from the polymerization of one or more hydrophilic monomers (e.g., 2-hydroxyethyl methacrylate (HEMA) or vinyl alcohol), optionally in combination with other monomers, and do not contain siloxane molecules. The polymer lens body of the hydrogel contact lens may, for example, be a reaction product of a polymerizable composition comprising at least one monomer of N-vinyl pyrrolidone, (hydroxyethyl) methacrylate, glycidyl methacrylate, ethylene glycol dimethacrylate and / or polycarbonate, or any combination thereof, wherein the composition is optionally free of siloxane monomers or macromers.

[0069] The hydrogel contact lens may be a silicone hydrogel. As an example, the silicone hydrogel contact lens comprises a polymer lens body that is the reaction product of a polymerizable composition comprising at least one siloxane monomer or macromer and at least one hydrophilic monomer and / or at least one hydrophilic polymer. Conveniently, as described in more detail below, the cured polymer lens body for the silicone hydrogel may be extracted in an extraction solvent containing a glycerophospholipid. Thus, a desired amount of glycerophospholipid becomes associated with the polymer lens body. The glycerophospholipid may be attached to the polymer lens body by electrostatic and / or hydrophobic interactions, and / or may be physically embedded by the polymer network of the polymer lens body. Alternatively, or in addition, the glycerophospholipid may be added to the polymerizable composition, for example, prior to curing.

[0070] Advantageously, the hydrogel (i.e., conventional hydrogel or silicone hydrogel) is neutral or positively charged (i.e., cationic), preferably neutral. The term "neutral" refers to units derived from nonionic or zwitterionic molecules. The presence of an overall negative charge has been found to inhibit the activity of the sPLA2 enzyme and thus reduce C 12 -C 26 Release of fatty acids from the glycerophospholipid-containing contact lenses. Preferably, the contact lenses do not contain anionic units, such as units derived from methacrylic acid (MAA) or 2-methacryloyloxyethyl phosphate (MOEP).

[0071] The polymer lens body typically has an equilibrium water content (EWC) of at least 40%, such as at least 45%. Advantageously, the hydrogel contact lens is a high water content contact lens having a polymer lens body with an EWC of at least 50%. The contact lens may be a US Food and Drug Administration (FDA) Group II non-ionic high water content lens or a FDA Group IV ionic high water content lens, which is a cationic or silicone hydrogel contact lens with an EWC of at least 40% or at least 45%. Advantageously, the contact lens is a FDA Group II non-ionic high water content lens or a silicone hydrogel contact lens with an EWC of at least 40% or at least 45%. It has been found that an EWC greater than 40% leads to increased sPLA2 enzyme activity, thereby leading to fatty acid release.

[0072] The amount of glycerophospholipids "loaded into" or "associated with" the polymer lens body refers to the total amount of glycerophospholipids that can be extracted from the contact lens by an isopropyl alcohol (IPA) extraction method as described in Example 2 below. The glycerophospholipids associated with the polymer lens body can be embedded in the matrix of the polymer material or attached to the polymer material, for example, by hydrogen bonding or electrostatic interactions. Advantageously, the glycerophospholipids associated with the polymer lens body are not removed when the lens is immersed in deionized water or a standard contact lens packaging solution, such as phosphate buffered saline or phosphate buffered saline containing 75 ppm polyvinylpyrrolidone (PVP). Advantageously, when the lens is immersed in 5 mL of deionized water, no more than 20% by weight, especially no more than 10% by weight, of the glycerophospholipids are extracted from the polymer lens body into deionized water. In one example, the glycerophospholipids are loaded into the polymer lens body contained in a loading solution comprising an alcohol (e.g., ethanol) and 2-oleoyl phospholipids in the range of 1 to 10 mg / mL. The loading solution may, for example, comprise about 60% ethanol and about 40% water. In a particular example, the loading solution comprises 2 mg / mL glycerophospholipid. The lens may be immersed in the loading solution for 3 hours at 25° C. to load the glycerophospholipid to the polymer lens body. In another example, the amount of 2-oleoyl phospholipid associated with the polymer lens body may be at least about 1 μg, 25 μg, 50 μg, 100 μg, 200 μg or 300 μg up to about 400 μg, 500 μg, 600 μg, 700 μg, 800 μg, 900 μg or 1000 μg, for example, about 300 μg to about 1000 μg. Preferably, the amount of glycerophospholipid associated with the polymer lens body is 100 μg to 1000 μg, especially 300 μg to 800 μg.

[0073] The glycerophospholipid may have formula (I):

[0074]

[0075] Where X is –O– or –O(CO)–, R 1 and R 2 Each independently is C 11-25 Alkyl, and R 3 is selected from hydrogen, C 1-10 polyols, ethanolamine (-CH2CH2NH2) and serine (-CH2CH(NH2)COOH), or salts of glycerophospholipids of formula (I) (e.g., wherein R 3 is a negative charge, or R 3 For protonated ethanolamine: -CH2CH2NH3 + ).

[0076] R 1 and R 2 Each is independently a saturated or unsaturated alkyl group, and unless otherwise specified, the term "alkyl" as used herein refers to both aliphatic groups having a saturated alkyl chain and groups having an unsaturated alkenyl chain. 1 and R 2 R may each independently have a straight (ie, unbranched) or branched alkyl or alkenyl chain. 1 and R 2 Each independently is unsubstituted or substituted, for example, by hydroxyl, C 1-12 alkyl (such as methyl, ethyl, propyl or butyl), polyethylene glycol (PEG), sugar, epoxy and any combination thereof, especially unsubstituted or substituted with hydroxyl or methyl. 1 and R 2 Each independently is C 11-23 , especially C 13-21 Alkyl, where R 1 and R 2 Each is independently optionally unsaturated and contains at least one unsaturated C=C double bond. Optionally, R 1 and R 2 Each independently is -(CH2) 7-11 CH=CH(CH2) 1-9 CH3, or -(CH2) 8-10 CH=CH(CH2) 1-7 CH3, for example -(CH2) 10 CH=CH(CH2)1CH3, -(CH2)8CH=CH(CH2)7CH3 or -(CH2) 10 CH=CH(CH2)3CH3. Optionally, R 1 and R 2Each is independently oleoyl, oleic acid, which has the IUPAC name: (9Z)-octadec-9-enoic acid. 1 and R 2 Each independently is -(CH2) 1-4 [CH=CH(CH2) 1-2 ] 3-7 CH3, for example -(CH2)2[CH=CH(CH2)]6CH3. Optionally, R 1 and R 2 Each is independently docosahexaenoyl, docosahexaenoic acid, which has the IUPAC name (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid. Advantageously, R 2 C 11-25 Unsaturated alkyl, preferably C 11-23 Alkyl groups, for example C containing at least one unsaturated C=C double bond, preferably one C=C double bond 13-21 Alkyl. 2 Optionally, R 2 -(CH2) 7-11 CH=CH(CH2) 1-9 CH3 or -(CH2) 8-10 CH=CH(CH2) 1-7 CH3, for example -(CH2) 10 CH=CH(CH2)1CH3, -(CH2)8CH=CH(CH2)7CH3 or -(CH2) 10 CH=CH(CH2)3CH3. 2 It may be selected from oleoyl, palmitoyl, stearoyl or docosahexenoyl, for example oleoyl or docosahexenoyl, especially oleoyl. Advantageously, R 1 C 11-25 Unsaturated alkyl, preferably C 11-23 Alkyl groups, for example C containing at least one unsaturated C=C double bond, preferably one C=C double bond 13-21 Optionally, R 1 has a straight (ie, non-branched) alkyl chain. Optionally, R 1 -(CH2) 7-11 CH=CH(CH2) 1-9 CH3 or -(CH2) 8-10 CH=CH(CH2) 1-7 CH3, for example -(CH2) 10 CH=CH(CH2)1CH3, -(CH2)8CH=CH(CH2)7CH3 or -(CH2)10 CH=CH(CH2)3CH3. 1 It may be selected from oleoyl, palmitoyl, stearoyl or docosahexenoyl.

[0077] R 3 is selected from hydrogen, C 1-10 Polyols, ethanolamine (-CH2CH2NH2) and serine (-CH2CH(NH2)COOH) and their salts, especially C 1-10 Polyols and ethanolamine (-CH2CH2NH2) and their salts. 3 Advantageously selected from -CH2CH2NH2 and -CH2CH(OH)CH2OH. Polyol is an organic compound containing multiple hydroxyl groups. Optionally, the glycerophospholipid is a phosphatidylglycerol. Non-limiting examples of suitable glycerophospholipids include 1,2-dioleoylphosphatidylglycerol, 1,2-dimyristoylphosphatidylglycerol, 1,2-di(pentadecanoyl)phosphatidylglycerol, 1-myristoyl-2-oleoylphosphatidylglycerol, 1-pentadecanoyl-2-oleoylphosphatidylglycerol, 1-palmitoyl-2-oleoylphosphatidylglycerol, 1-stearoyl-2-oleoylphosphatidylglycerol, 1,2-di(docosahexadecanoyl)phosphatidylglycerol Phosphatidylglycerol, 1-oleoylphos ...

[0078] As used herein and unless the context indicates otherwise, reference to releasing C from a 12-26 Fatty acids released from contact lenses 12 -C 26 The amount of fatty acid or C 12 -C 26 The "release profile" of the fatty acid refers to the C released from the lens measured using an in vitro release medium (ATF as described in Table 1 below supplemented with 50 ppm PLA2-IIA (e.g., recombinant human Group IIA phospholipase 2-acyl hydrolase enzyme or bee venom sPLA2), as described in Example 4 below). 12 -C 26 The contact lens may have a release medium of at least 0.05 μg / hr, or 0.05 μg / hr to 50 μg / hr C after initial immersion in the release medium at 35°C. 12-26Fatty acids, for example, from 0.1 μg / hr to 25 μg / hr, or 0.5 μg / hr to 10 μg / hr, or 1 μg / hr to 5 μg / hr C of the lens 12 -C 26 In vitro C of fatty acids 12-26 Fatty acid release profile. Advantageously, the contact lens releases C 12-26 The fatty acid is released from the lens for at least 4 hours, such as at least 8 hours, and optionally at least 10 hours. Advantageously, the contact lens releases 0.05 μg / hr to 50 μg / hr per hour from the lens for at least the first 10 hours after immersion in the release medium at 35°C. 12-26 Fatty acids, for example, 0.01 μg / hr to 25 μg / hr, or 0.5 μg / hr to 10 μg / hr, or 1 μg / hr to 5 μg / hr C 12 -C 26 Fatty acids. Thus, the contact lenses of the present invention loaded with the phospholipid of formula (I) may have a C of at least 0.05 μg / hr, preferably at least 0.1 μg / hr, such as 0.1 μg / hr to 25 μg / hr, such as 0.5 μg / hr to 10 μg / hr, or 1 μg / hr to 5 μg / hr over a period of at least 4 hours, such as at least 8 hours, and optionally at least 10 hours. 12 -C 26 In vitro C of fatty acids 12-26 Fatty acid release profiles were obtained by placing the lenses into a 6 mL glass file containing 3 mL of in vitro release medium (ATF with 50 ppm sPLA2 added as described in Table 1), shaking the vial at 50 rpm in a 35°C incubator, and removing 2.5 ml of release medium samples from the vial at 2 hour increments (e.g., 2 hr, 4 hr, 6 hr, 8 hr, and 10 hr) and analyzing the samples by liquid chromatography-mass spectrometry (LCMS) for C 12 -C 26 Fatty acid content was determined by replacing 2.5 ml of fresh release medium into the vial and continuing to incubate the lenses in the vial on the shaker for an additional 2 hours until the next increment.

[0079] As an option, the contact lenses of the present invention do not contain any comfort agents other than the presence of the glycerophospholipids as described herein.

[0080] As an option, the contact lenses of the present invention may contain one or more comfort agents other than the glycerophospholipids described herein. The amount of any other comfort agent may be less than the amount of glycerophospholipids present. The amount of any other comfort agent may be less than 300 ug, less than 100 ug, less than 50 ug, less than 10 ug, or less than 1 ug.

[0081] As an option, the packaging solution as described herein does not contain any comfort agent.

[0082] As an option, the packaging solution as described herein does not contain any comfort agent, except for the possible presence of glycerophospholipids and / or fatty acids resulting from the glycerophospholipids initially present in the contact lens.

[0083] As an option, the only phospholipids present in or associated with the contact lens are glycerophospholipids.

[0084] As an option, the only source of fatty acids released or present in the contact lens is from the glycerophospholipids present.

[0085] Compared to free fatty acids (not derived from glycerophospholipids) associated with the contact lens, the present invention has the ability to provide improved controlled release of fatty acids. For example, compared to free fatty acids used / associated with the contact lens alone, the release may be more linear.

[0086] The release of the fatty acids through digestion of glycerophospholipids can be regarded as tear-controlled release of fatty acids.

[0087] The polymer lens body may include any hydrogel material suitable for use as a contact lens material. Non-polysilicone hydrogel materials for contact lenses are generally formed by curing a polymerizable composition (i.e., a monomer mixture) comprising at least one hydrophilic monomer or at least one hydrophilic polymer or a combination thereof. The polymerizable composition used to form non-polysilicone hydrogel lens materials generally does not contain or substantially does not contain a silicon-containing component, especially does not contain or substantially does not contain a siloxane monomer or a macromolecular monomer. The polymerizable composition used to form non-polysilicone hydrogel lens materials may contain no more than 3% by weight of a silicon-containing component, especially no more than 2% by weight of a silicon-containing component, for example no more than 1% by weight of a silicon-containing component. The polysilicone hydrogel material for contact lenses is generally formed by curing a polymerizable composition (i.e., a monomer mixture) comprising at least one siloxane monomer or a macromolecular monomer and at least one hydrophilic monomer or at least one hydrophilic polymer or a combination thereof. As used herein, the term "siloxane monomer" refers to a molecule comprising at least one Si-O group and at least one polymerizable functional group. "Siloxane macromer" refers to a silicon-containing molecule having at least one polymerizable functional group which, while acting as a monomer, has a sufficiently high molecular weight and sufficient internal monomer units to be considered polymerized. Typically, the siloxane macromer contains a siloxane chain having at least 5 siloxane (-Si-O-) units and / or has a molecular weight of at least 500 Daltons.

[0088] Siloxane monomers and macromers used in contact lens compositions are well known in the art (see, e.g., U.S. Pat. No. 8,658,747 and U.S. Pat. No. 6,867,245). (All patents and publications mentioned herein and throughout are incorporated by reference in their entirety.) In some examples, the polymerizable composition comprises a total amount of at least 10 wt%, 20 wt%, or 30 wt% up to about 40 wt%, 50 wt%, 60 wt%, or 70 wt% of siloxane monomers or macromers. Unless otherwise indicated, as used herein, given weight percentages (wt%) of components of the polymerizable composition are relative to the total amount of all polymerizable ingredients and interpenetrating polymer network (IPN) polymers (as further described below) in the polymerizable composition. The weight of the polymerizable composition contributed by components that are not incorporated into the final contact lens product (e.g., diluent) is not included in the wt% calculation.

[0089] In a specific example, the polymerizable composition comprises a hydrophilic vinyl monomer. As used herein, a "hydrophilic vinyl monomer" is any siloxane-free (i.e., Si-O-free) hydrophilic monomer having a polymerizable carbon-carbon double bond (i.e., a vinyl group) that is not part of an acrylic group in its molecular structure, wherein the carbon-carbon double bond of the vinyl group is not as reactive as the carbon-carbon double bond present in a polymerizable methacrylate group under free radical polymerization. As used herein, the term "acrylic group" refers to a polymerizable group present in acrylates, methacrylates, acrylamides, and the like. Thus, although carbon-carbon double bonds are present in acrylate and methacrylate groups, such polymerizable groups are not considered vinyl groups as used herein. In addition, as used herein, a monomer is "hydrophilic" if at least 50 grams of the monomer is completely soluble in 1 liter of water (i.e., about 5% soluble in water) at 20°C as determined visibly using a standard shaking flask method. In various examples, the hydrophilic vinyl monomer is N-vinyl-N-methylacetamide (VMA), or N-vinyl pyrrolidone (NVP), or 1,4-butanediol vinyl ether (BVE), or ethylene glycol vinyl ether (EGVE), or diethylene glycol vinyl ether (DEGVE), or any combination thereof. In one embodiment, the polymerizable composition comprises at least 10 wt%, 15 wt%, 20 wt%, or 25 wt% up to about 45 wt%, 60 wt%, or 75 wt% of the hydrophilic vinyl monomer. As used herein, a given weight percentage of a particular class of components (e.g., hydrophilic vinyl monomers, siloxane monomers, etc.) in the polymerizable composition is equal to the sum of the weight % of each ingredient in the composition that falls within the class. Thus, for example, a polymerizable composition comprising 5 wt% BVE and 25 wt% NVP and no other hydrophilic vinyl monomers is said to comprise 30 wt% hydrophilic vinyl monomers. In one example, the hydrophilic vinyl monomer is a vinylamide monomer. Exemplary hydrophilic vinylamide monomers are VMA and NVP. In a particular example, the polymerizable composition comprises at least 25 wt% of the vinylamide monomer. In another particular example, the polymerizable composition comprises from about 25 wt% up to about 75 wt% of VMA or NVP, or a combination thereof. Additional hydrophilic monomers that may be included in the polymerizable composition are N,N-dimethylacrylamide (DMA), 2-hydroxyethyl methacrylate (HEMA), ethoxyethyl methacrylamide (EOEMA), ethylene glycol methyl ether methacrylate (EGMA), and combinations thereof.

[0090] In addition to or as an alternative to hydrophilic monomers, the polymerizable composition may include a non-polymerizable hydrophilic polymer that produces a polymer lens body comprising an interpenetrating polymer network (IPN), wherein the non-polymerizable hydrophilic polymer interpenetrates the silicone hydrogel polymer matrix. In the present example, the non-polymerizable hydrophilic polymer is referred to as an IPN polymer, which is used as an internal lubricant in a contact lens. In contrast, polymer chains within the silicone hydrogel network formed by polymerization of monomers present in the polymerizable composition are not considered to be IPN polymers. The IPN polymer may be a high molecular weight hydrophilic polymer, such as about 50,000 to about 500,000 Daltons. In a specific example, the IPN polymer is polyvinyl pyrrolidone (PVP). In other examples, the polymerizable composition is substantially free of polyvinyl pyrrolidone or other IPN polymers.

[0091] As an option, one or more non-silicon containing hydrophobic monomers may be present as part of the polymerizable composition.A hydrophobic monomer is understood to be any monomer for which 50 grams of monomer is not visibly completely soluble in 1 liter of water at 20°C as determined using the standard shake flask method. Examples of suitable hydrophobic monomers include methyl acrylate, or ethyl acrylate, or propyl acrylate, or isopropyl acrylate, or cyclohexyl acrylate, or 2-ethylhexyl acrylate, or methyl methacrylate (MMA), or ethyl methacrylate, or propyl methacrylate, or butyl acrylate, or 2-hydroxybutyl methacrylate, or vinyl acetate, or vinyl propionate, or vinyl butyrate, or vinyl valerate, styrene, or chloroprene, or vinyl chloride, or vinylidene chloride, or acrylonitrile, or 1-butene, or butadiene, or methacrylonitrile, or vinyl toluene, or vinyl ethyl ether, or perfluorohexylethylthiocarbonylaminoethyl methacrylate, or isoborneol methacrylate (IBM), or trifluoroethyl methacrylate, or hexafluoroisopropyl methacrylate, or tetrafluoropropyl methacrylate, or hexafluorobutyl methacrylate, or any combination thereof.

[0092] The hydrophobic monomer, if used, can be present in the reaction product of the polymerizable composition in an amount from 1 wt % to about 30 wt % (e.g., 1 wt % to 25 wt %, 1 wt % to 20 wt %, 1 wt % to 15 wt %, 2 wt % to 20 wt %, 3 wt % to 20 wt %, 5 wt % to 20 wt %, 5 wt % to 15 wt %, 1 wt % to 10 wt %) based on the total weight of the polymerizable composition.

[0093] The polymerizable composition may additionally include at least one crosslinking agent. As used herein, a "crosslinking agent" is a molecule having at least two polymerizable groups. Thus, a crosslinking agent can react with functional groups on two or more polymer chains in order to bridge one polymer to another. The crosslinking agent may include an acrylic or vinyl group, or both an acrylic and vinyl group. In certain instances, the crosslinking agent does not contain a siloxane moiety, that is, it is a non-siloxane crosslinking agent. Various crosslinking agents suitable for use in silicone hydrogel polymerizable compositions are known in the art (see, e.g., U.S. Pat. No. 8,231,218, which is incorporated herein by reference). Examples of suitable crosslinking agents include, but are not limited to, lower alkylene glycol di(meth)acrylates, such as triethylene glycol dimethacrylate, diethylene glycol dimethacrylate, poly(lower alkylene) glycol di(meth)acrylates, and lower alkylene di(meth)acrylates; divinyl ethers, such as triethylene glycol divinyl ether, diethylene glycol divinyl ether, 1,4-butanediol divinyl ether, and 1,4-cyclohexanedimethanol divinyl ether; bisvinyl sulfone; di- and trivinylbenzene; trimethylolpropane tri(meth)acrylate; pentaerythritol tetra(meth)acrylate; bisphenol A di(meth)acrylate; methylenebis(meth)acrylamide; triallyl phthalate; 1,3-bis(3-methacryloxypropyl)tetramethyldisiloxane; diallyl phthalate; and combinations thereof.

[0094] As is understood by those skilled in the art, the polymerizable composition may include other polymerizable or non-polymerizable ingredients conventionally used in contact lens formulations, such as one or more of polymerization initiators, UV absorbers, colorants, oxygen scavengers, chain transfer agents, etc. In some examples, the polymerizable composition may include an organic diluent in an amount that can prevent or minimize phase separation between the hydrophilic and hydrophobic components of the polymerizable composition, so as to obtain optically clear lenses. Diluents commonly used in contact lens formulations include hexanol, ethanol, and / or other primary, secondary, or tertiary alcohols. In other examples, the polymerizable composition is free of or substantially free of (e.g., less than 500 ppm) organic diluents. In such examples, the use of siloxane monomers containing hydrophilic moieties (e.g., polyethylene oxide groups, side hydroxyl groups, or other hydrophilic groups) may make it unnecessary to include a diluent in the polymerizable composition. Non-limiting examples of these and other ingredients that may be included in the polymerizable composition are provided in U.S. Pat. No. 8,231,218.

[0095] Non-limiting examples of silicone hydrogels that can be used include comfilcon A, fanfilcon A, senofilcon A, senofilcon C, somofilcon A, narafilcon A, delefilcon A, nalafilcon A, lotrafilcon A, lotrafilcon B, balafilcon A, samfilcon A, galyfilcon A, and asmofilcon A.

[0096] A specific example of the hydrogel contact lens of the present invention is a contact lens based on a polymerizable composition, wherein the polymerizable composition comprises 25 wt% to 55 wt% of a siloxane monomer or macromonomer, 30 wt% to 55 wt% of a vinyl monomer selected from NVP, VMA or a combination thereof, and optionally about 1 wt% to about 20 wt% of a hydrophilic monomer selected from N,N-dimethylacrylamide (DMA), 2-hydroxyethyl methacrylate (HEMA), ethoxyethyl methacrylamide (EOEMA) or ethylene glycol methyl ether methacrylate (EGMA) or any combination thereof, and optionally about 1 wt% to about 20 wt% of a hydrophobic monomer selected from methyl methacrylate (MMA), isobornyl methacrylate (IBM) or 2-hydroxybutyl methacrylate (HOB) or any combination thereof. The silicone hydrogel materials made from this specific embodiment of the polymerizable composition include Stanfecon A, Canfecon A, Shamofecon A, Vanfecon A and Enfilcon A. In another example, the polymerizable composition comprises a siloxane of Stanfecon A, specifically a first siloxane having a structure represented by formula (II),

[0097]

[0098] and a second siloxane having a structure represented by formula (III),

[0099]

[0100] Conventional methods can be used to make the contact lenses of the present invention. As an example, a polymerizable composition for a hydrogel composition is dispensed into a female mold member having a concave surface defining the front surface of the contact lens. A male mold member having a convex surface defining the back surface (i.e., corneal contact surface) of the contact lens is combined with a female mold member to form a contact lens casting mold assembly, which is subjected to curing conditions (e.g., UV or thermal curing conditions), under which the curable composition is formed into a polymer lens body. The female mold and male mold members may be non-polar casting molds or polar casting molds. The casting mold assembly is disassembled (i.e., demolded) and the polymer lens body is removed from the casting mold and contacted with a solvent (e.g., an organic solvent, such as ethanol) to extract unreacted components from the lens body. After extraction, the lens body is hydrated in one or more hydrating liquids (e.g., water or an aqueous solution) and packaged. An exemplary method for making a silicone hydrogel contact lens is described in U.S. Pat. No. 8,865,789.

[0101] The glycerophospholipids are typically loaded into the polymer lens during the extraction step. Generally, after solidification, the polymer lens body is swollen in an extraction solvent (e.g., ethanol) containing the glycerophospholipids. When the extracted polymer lens body is subsequently placed in a hydration solution (e.g., deionized (DI) water), the extraction solvent is removed and the glycerophospholipids remain associated with the polymer lens body.

[0102] Examples of extraction solvents and hydration liquids used in the extraction and hydration process may consist of denatured ethanol, a 50 / 50 (by volume) mixture of denatured ethanol and deionized water, and deionized water. As an example, the extraction and hydration process may involve at least one extraction step in denatured ethanol followed by a 50:50 mixture of ethanol water, followed by at least one hydration step in deionized water, and wherein each extraction and hydration step may last for about 15 minutes to about 3 hours at a temperature of about 20° C. to about 30° C. An extraction solvent may contain 2-oleoyl phospholipids to enable loading of the 2-oleoyl phospholipids onto the polymer lens body.

[0103] Any extraction solvent used as a loading solution for the glycerophospholipids may contain a concentration of 1 to 50 mg / mL, such as 2 to 20 mg / mL of glycerophospholipids. This concentration may be at least 1 mg / mL, at least 3 mg / mL, at least 5 mg / mL, or at least 10 mg / mL of glycerophospholipids. In one example, the concentration of glycerophospholipids in the extraction solvent is about 2 to about 20 mg / mL, such as 3 to 10 mg / ml. The amount of glycerophospholipids loaded into the polymer lens body may be 1 μg to 1000 μg. The amount of glycerophospholipids loaded into the polymer lens body may be at least 100 μg, at least 200 μg, or at least 500 μg. Preferably, the amount of glycerophospholipids loaded into the polymer lens body is at least 300 μg, such as 300 μg to 1000 μg.

[0104] In some examples, the glycerophospholipids are stable once loaded into the polymer lens body and are not substantially released or degraded from the polymer lens body during the steaming process of a sealed contact lens package containing an unworn hydrogel contact lens contained in a packaging solution, or during storage of its packaging solution. Thus, the packaging solution in which the contact lens is immersed releases less than 10 ppm of the glycerophospholipids comprising C from the contact lens before or immediately after steaming, or after 1 day at 25° C., or after 30 days at 25° C., or after 60 days at 25° C., or after 120 days at 25° C. 12 -C 26 The glycerophospholipids with acyl groups at the sn-2 position enter the packaging solution or are released from the contact lens at less than 5 ppm or less than 1 ppm or 0 ppm into the packaging solution. Advantageously, no more than 20 wt.%, especially less than 10 wt.%, preferably less than 5 wt.% of the glycerophospholipids associated with the polymer lens body are released into the packaging solution after storage at 25°C for at least 1 day. Whether the glycerophospholipids are released from the contact lens during the steaming process or storage can be determined by testing the presence of the glycerophospholipids in the packaging solution using LCMS or other suitable analytical methods.

[0105] As part of the present invention, the contact lens can be sealed in a contact lens package. The packaging solution sealed in the contact lens package can be any conventional contact lens compatibility solution. In one example, the packaging solution comprises an aqueous solution of a buffer and / or a tonicity agent, is composed of it, or is substantially composed of it. In another example, the packaging solution contains additional agents, such as one or more additional antimicrobial agents, and / or comfort agents, and / or hydrophilic polymers, and / or surfactants and / or other beneficial agents. In some examples, the packaging solution can include polysaccharides (such as hyaluronic acid, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, etc.) or other high molecular weight polymers, such as polyvinyl pyrrolidone, which is commonly used as a comfortable polymer or thickener in ophthalmic solutions and contact lens packaging solutions. In other examples, the packaging solution can include ophthalmic drugs. The packaging solution can have a pH in the range of about 6.8 or 7.0 up to about 7.8 or 8.0. In one example, the packaging solution includes a phosphate buffer or a borate buffer. In another example, the packaging solution comprises a tonicity agent selected from sodium chloride or sorbitol in an amount to maintain osmotic pressure in the range of about 200 to 400 mOsm / kg, and typically about 270 mOsm / kg up to about 310 mOsm / kg.

[0106] It should be understood that conventional manufacturing methods can be used to manufacture sealed contact lens packaging. In the method for manufacturing contact lens packaging, the method may include the following steps: placing unworn contact lenses and contact lens packaging solution in a container, placing a cover on the container, and sealing the cover on the container. In general, the container is configured to receive a single contact lens and an amount of packaging solution sufficient to completely cover the contact lens, typically about 0.5 to 1.5 ml. The container can be made of any suitable material (e.g., glass or plastic). In one example, the container is in the form of a plastic base member comprising a plurality of threads and the cover comprises a plastic cap member, the plastic cap member comprising a group of compatible threads for providing a resealable cover with the thread engagement of the base member. It should be understood that other types of packaging can also be used to provide resealable packaging. For example, the contact lens packaging may include a plastic cover, the plastic cover comprising a compatible feature engagement with the container to form a tight fit feature. The method for manufacturing sealed contact lens packaging may further include sterilizing unworn contact lenses by dense steaming the sealed contact lens packaging. Sealing treatment generally involves subjecting the sealed contact lens package to a temperature of at least 121°C for at least 20 minutes.

[0107] The contact lens may be unworn (i.e., a new contact lens, not previously used by the patient), immersed in a packaging solution and sealed in a package. The package may be a blister package, a glass vial, or other suitable container. The package may include a base member having a cavity for retaining the packaging solution, a cover forming a fluid-tight seal with the base member, and an unworn contact lens. The sealed package may be sterilized by a sterilizing amount of radiation (including heat or steam), such as by steaming or by gamma radiation, electron beam radiation, ultraviolet radiation, and the like.

[0108] In a specific example, the packaged contact lenses are sterilized by steaming.

[0109] The final product can be a sterile, packaged contact lens (eg, a silicone hydrogel contact lens) having ophthalmologically acceptable surface wettability.

[0110] The release of C 12 -C 26 Hydrogel contact lenses containing fatty acids can be used to correct the vision of symptomatic contact lens wearers. For example, the hydrogel contact lenses of the present invention release C 12 -C 26 A fatty acid hydrogel contact lens can increase the duration of comfortable contact lens wear time in symptomatic contact lens wearers. References herein to "symptomatic contact lens wearers" or "symptomatic subjects" refer to lens wearers classified as symptomatic using the CLDEQ-8 described by Chalmers et al. (See Chalmers et al., Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and Perception of Contact Lens Performance. Optometry and Visual Science 2012;89(10):1435-1442.). Compared to control lenses or the usual lenses of the control lens wearers, the C-released contact lens described herein can be used to increase the duration of comfortable contact lens wear time in symptomatic contact lens wearers. 12 -C 26 Hydrogel contact lenses containing fatty acids may be worn by contact lens wearers to reduce lens perception and / or result in fewer "lens perception events" during the day. Reference herein to "control lenses" refers to lenses that do not contain phospholipids or C 12 -C 26 fatty acids but otherwise released C 12 -C 26The same contact lenses as the lenses of fatty acids. Reduction in lens perception and / or lens perception events during contact lens wear can be determined using an "eye perception logger" as described by Read et al. (See Read et al., Monitoring ocular discomfort using a wrist-mounted electronic logger. Contact Lens and Anterior Eye, Vol. 43 (2020) 476-483).

[0111] Examples

[0112] The following examples illustrate certain aspects and advantages of the present invention, which should not be construed as being limiting thereof.

[0113] Example 1. Assay for susceptibility to phospholipid digestion by sPLA2-IIA.

[0114] Each phospholipid loaded lens was removed from its packaging and placed in a 6 mL glass vial containing 5 mL of ATF described in Example 2 at room temperature on a shaker at 125 rpm overnight to elute any free fatty acids that may be present in the lenses.

[0115] Prior to running the digestion assay, each lens was rinsed for 30 minutes in a 6 ml glass vial containing a fresh aliquot of 5 mL ATF.

[0116] A 50 ppm solution of sPLA2 was prepared in ATF by adding 200 μl ATF to a tube containing 10 μg of recombinant human PLA2G2A (Creative BioMart, catalog number PLA2G2A-669H). The solution is called ATF+sPLA2. As an option, human reflex tears can be used instead of ATF+sPLA2. Two 4 mm pieces were cut from each eyeglass. One piece of each eyeglass was placed in a tube with 100 μL ATF and the other piece was placed in a tube containing 100 μL ATF+sPLA2. The tubes were incubated at 35±2°C for 4 hours without shaking.

[0117] 50 μl of release medium from each lens at T=4 hr was transferred to an HPLC vial and 500 μl of isopropyl alcohol (IPA) was added and mixed thoroughly. A T=0 hr HPLC vial (50 μl ATF + 500 μl IPA) was also prepared. All vials were sonicated for 15 minutes and centrifuged. The supernatant was removed for LCMS injection.

[0118] The supernatant was injected on an LCMS instrument equipped with an ACQUITY UPLC BEH C18 1.7 μg, 2.1 mm x 15 cm column and running a mobile phase gradient of 65% A to 90% B at a flow rate of 0.35 mL / min, wherein A = 40% acetonitrile in water containing 10 mM ammonium acetate and 0.2% (v / v) ammonium hydroxide, and B = 10% acetonitrile IPA solution containing 10 mM ammonium acetate and 0.2% (v / v) ammonium hydroxide. The mass spec detector was operated in negative electrospray mode. The peaks of the specific fatty acids of interest (i.e., fatty acids released from the sn-2 position of the phospholipids in the contact lens) in the supernatant were measured. The ratio of the fatty acid peak areas in the ATF with and without sPLA2 was calculated.

[0119] Example 2. sPLA2-mediated phospholipid digestion of Stanfecon A glasses loaded with different phospholipids.

[0120] The phospholipids shown in Table 1 were obtained from Avanti Polar Lipids. A 3 mg / ml loading solution of the phospholipids shown in Table 1 was prepared by adding 2.4 mL of ethanol to 9 mg of phospholipids, sonicating (up to 14 minutes), then adding 0.6 mL of DI water and sonicating again (up to 15 minutes) to dissolve the phospholipids.

[0121] Table 1.

[0122]

[0123]

[0124] Hydrated contact lenses made of Steinfecon A were washed three times in 3 mL of pure water for 30 minutes each. Each washed lens was placed in 3 mL of phospholipid loading solution and incubated at 75 rpm for 3 hours at room temperature with gentle shaking. The loaded lenses were then rinsed and hydrated with several exchanges of DI water. The lenses were packaged in buffered saline contact lens packaging solution and subjected to dense steam treatment.

[0125] Artificial tear solution (ATF) was prepared by adding the first three ingredients listed in Table 2 to a clean grade vial and then adding 30 mL of the fourth ingredient.

[0126] Table 2.

[0127]

[0128] After dense steam treatment, each lens was tested for susceptibility to phospholipid digestion by sPLA2-IIA using the method described in Example 1. The peak of oleic acid (OA) (m / z trace = 281.24) was measured in the supernatant submitted to LCMS analysis. The ratio of OA in ATF with and without sPLA2 was calculated. The results are shown in Table 3.

[0129] Table 3. Oleic acid peak area in ATF with and without sPLA2.

[0130] sample ATF ATF+sPLA2 ratio DOPG 36 9958 279 DOPE 463 2127 4.6 DOPC 102 125 1.2 DOPS 88 1437 16.4

[0131] The results indicate that contact lenses loaded with 2-oleoylphosphatidylcholine are less susceptible to sPLA2-mediated degradation and fatty acid release whereas contact lenses loaded with phosphatidylglycerol, phosphatidylethanolamine, and phosphatidylserine are less susceptible to sPLA2-mediated fatty acid release.

[0132] Example 3. DOPG-loaded Stanfecon A contact lenses

[0133] 1,2-Dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG) from Sigma-Aldrich was dissolved in 50 vol% ethanol (EtOH) 50 vol% deionized water solution and sonicated until the DOPG was completely dissolved to provide a DOPG loading solution in the concentration range of 1 mg / ml to 10 mg / ml.

[0134] Silicone hydrogel contact lenses were prepared by curing the formulation of Stanfecon A in a polypropylene contact lens casting mold. The cured Stanfecon A was removed from the casting mold, and each lens was extracted in EtOH to remove unreacted monomers. The lenses were then placed in the DOPG loading solution for about 90 minutes and then hydrated with several exchanges of DI water. The lenses were packaged in plastic blisters with about 1.2 ml of a packaging solution containing phosphate buffered saline (PBS) and subjected to a dense steam treatment.

[0135] The amount of DOPG in each lens was determined by extracting the lens with isopropyl alcohol (IPA) and measuring the DOPG in the extract by LCMS. Briefly, each lens was removed from its blister pack, lightly dotted to remove excess packaging solution, and placed in a 20 mL glass vial containing 10 mL of 100% IPA. The vial was placed on a bench top shaker at 300 rpm overnight (approximately 16 hours) at room temperature. For Stanfecon A, a single 2-hour extraction step was sufficient to extract substantially all of the DOPG from the lens. More hydrophobic silicone hydrogel lens materials may require a second overnight extraction in order to extract all of the DOPG, in which case the IPA from the first extraction step was removed and replaced with 3 mL of fresh IPA, then shaken overnight at 300 rpm at room temperature. The amount of DOPG in the IPA extract from each lens was determined by LCMS compared to a DOPG standard solution. The DOPG loading concentration and average DOPG in each lens are shown in Table 4.

[0136] Table 4.

[0137] DOPG loading concentration Average amount of DOPG / glass 1.0mg / mL 240 μg 2.5mg / mL 495 μg 5.0mg / mL 760μg 7.5mg / ml 895μg 10.0mg / ml 975μg

[0138] Example 4. Determination of fatty acid release profile

[0139] To determine the load including C 12 -C 26 Fatty acid release profiles from silicone hydrogel contact lenses of glycerophospholipids with acyl groups at the sn-2 position, the lenses were removed from their packaging and placed in a 6 mL glass vial containing 5 mL of ATF (described in Example 1) on a shaker at 125 rpm overnight at room temperature to elute any free fatty acids that may be present in the lenses.

[0140] Each lens was then transferred to a 6 mL glass vial containing 3 mL of ATF+sPLA2 in vitro release medium described in Example 1 at 35°C. As an alternative, phospholipase A2 from bee venom (Accession No. 9001-84-7) was used instead of the same concentration (50 ppm) of recombinant human PLA2G2A. The vials were placed on a shaker at 50 rpm and in 2 hour increments (e.g., 2 hr, 4 hr, 6 hr, 8 hr, and 10 hr) in a 35°C incubator. 2.5 ml of in vitro release medium was removed from each vial and submitted for analysis. If the release medium was not analyzed immediately at a particular time point, a sample was collected and mixed with IPA (1:10 v / v ratio) to stop enzymatic activity. Afterwards, 2.5 ml of fresh ATF+sPLA2 in vitro release medium was added back to each vial and the lenses continued to be incubated. At the end of the release experiment, the amount of fatty acids in the release medium at each time point was analyzed by LCMS using the method described in Example 1.

[0141] Example 5. Oleic acid release from 5 mg / mL DOPG loaded contact lenses (Lens A) and from 3 mg / mL DOPG loaded contact lenses (Lens B).

[0142] Silicone hydrogel contact lenses were prepared as in Example 2 using 5 mg / mL DOPG loading concentration (lens A) and 3 mg / mL DOPG loading concentration (lens B). The oleic acid release rate of lenses A and B was determined using the method of Example 4 using ATF release medium containing 50 ppm bee venom sPLA2 enzyme (accession number 9001-84-7). The oleic acid release in the in vitro release medium samples was tracked every 2 hours, and lenses A and B were respectively as follows: Figure 2 and 3 The results are shown in Table 5, where the cumulative oleic acid release at each time point (from T=0) is given.

[0143] Table 5.

[0144] time Average cumulative amount of A-OA released from glasses Average cumulative amount of B-OA released from glasses 2h 53.7 μg 38.5 μg 4hr 101.2 μg 75.6 μg 6hr 148.3 μg 110.4 μg 8hr 190.5 μg 141.1 μg 10hr 210.3 μg 165.8 μg

[0145] The results show a constant release of oleic acid that lasts for at least 10 hours for both lenses A and B. The approximate elution rates of oleic acid from lenses A and B are shown in Table 6.

[0146] Table 6.

[0147] Glasses DOPG loading concentration Average release rate of OA / glasses A 5mg / mL About 22 μg / hr B 3mg / mL About 17 μg / hr

[0148] Example 6. DHA release from different DHAPG loaded SiHy lenses.

[0149] Contact lenses prepared from Stanfecon A and Shamfecon A were soaked in 3 mg / mL DHAPG (1,2-di(docosahexaenoyl)-sn-glycero-3-[phospho-rac-(1-glycero)] (sodium salt) from Avanti Polar Lipids) dissolved in 50% ethanol. DHA release from DHAPG-loaded lenses was tested using the digestion assay of Example 1, except that ATF+sPLA2 reflex tears obtained from a single individual were used.

[0150] Based on the total DHA and DHAPG measured in the digested samples, the % DHAPG digested after 4 hours was determined by the following equation.

[0151] Digested DHAPG = (measured DHA*MW of DHAPG) / (MW of DHA)

[0152] Total DHAPG = Digested DHAPG + Measured DHAPG

[0153] Digestion % = Digested DHAPG / Total DHAPG

[0154] The results are shown in Table 7 and indicate that lens materials can affect sPLA2-mediated glycerophospholipid digestibility.

[0155] Table 7.

[0156]

[0157] The disclosure herein refers to certain illustrative examples, which should be understood to be presented by way of example and not by way of limitation. Although exemplary examples are discussed, the intent of the foregoing embodiments should be interpreted as covering all modifications, substitutions and equivalents of the examples, which may fall within the spirit and scope of the present invention as defined by the additional disclosure.

[0158] Reference herein to "one example" or "a specific example" or "an aspect" or "an embodiment" or similar phrases is intended to introduce the present invention into the context of the present invention. 12 -C 26 A fatty acid hydrogel contact lens or a component thereof, a sealed contact lens package or a component thereof, or a method for making a C-releasing contact lens of the present invention 12 -C 26One or more features of the method of preparing a hydrogel contact lens with fatty acids (depending on the context) can be combined with any combination of examples, aspects, embodiments (i.e., features) described previously or later, unless a particular combination of features is mutually exclusive or if the context indicates otherwise. In addition, as used in this specification, the singular forms "a", "an", and "the" include plural referents (e.g., at least one or more) unless the context clearly indicates otherwise. Thus, for example, reference to "a contact lens" includes a single lens as well as two or more of the same or different lenses.

[0159] All references cited in this disclosure are incorporated herein by reference in their entirety to the extent they are not inconsistent with this disclosure.

[0160] The present invention may include any combination of various features or embodiments described in the above text (including the above numbered items) and / or the following claims as stated in a sentence and / or paragraph. Any combination of features disclosed herein is considered part of the present invention and is not intended to limit the features that can be combined.

[0161] Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered exemplary only, with a true scope and spirit of the invention being indicated by the following claims and their equivalents.

Claims

1. An unworn hydrogel contact lens sealed in a package, the contact lens comprising at least one 12 -C 26 Acylglycerophospholipid polymer lenses.

2. The contact lens of claim 1, wherein the glycerophospholipid, when present in the polymer lens body, is susceptible to digestion by the secreted phospholipase 2-acyl hydrolase (sPLA2) enzyme found in human tears.

3. The contact lens according to claim 1, wherein the glycerophospholipid is of formula (I): Where X is –O– or –O(CO)–, R 1 and R 2 Each independently is C 11-25 Alkyl, and R 3 The group is selected from hydrogen, C 1-10 Polyols, ethanolamine and serine, and salts thereof.

4. The contact lens of claim 1, wherein the glycerophospholipid is phosphatidylserine, phosphatidylethanolamine or phosphatidylglycerol.

5. The contact lens of claim 1, wherein the contact lens is a silicone hydrogel contact lens.

6. The contact lens of claim 1, wherein the hydrogel is neutral or cationic.

7. The contact lens of claim 1, wherein the polymer lens body is the reaction product of a polymerizable composition comprising at least one hydrophilic monomer comprising a vinyl group.

8. The contact lens of claim 1, wherein the polymer lens body is a first siloxane comprising a structure represented by formula (II), and a polymerizable composition of a second siloxane having a structure represented by formula (III) 9. The contact lens of claim 1, wherein the hydrogel contact lens releases C when contacted with a solution comprising sPLA2-IIA. 12 -C 26 Fatty acids and their salts, of which C 12 -C 26 Fatty acids are the digestion products of the glycerophospholipids.

10. The contact lens of claim 1, wherein the glycerophospholipid is 1,2-dioleoylphosphatidylglycerol, 1-palmitoyl-2-oleoylphosphatidylglycerol, 1-stearoyl-2-oleoyl or 1,2-di(docosahexaenoyl)phosphatidylglycerol.

11. The contact lens of claim 1, wherein the polymer lens body is loaded with glycerophospholipid in an amount of 1 μg to 1000 μg, preferably at least 300 μg.

12. The contact lens of claim 1, wherein when the contact lens is immersed in a release medium comprising artificial tears containing 50 ppm sPLA2-IIA at 35°C, the contact lens continuously releases at least 0.1 μg / hr for at least 4 hours, such as at least 8 hours, and optionally at least 10 hours. 12 -C 26 Fatty acids, especially at least 0.5 μg / hr C 12 -C 26 fatty acid.

13. The contact lens of claim 1, wherein the glycerophospholipid is of formula (I): Where X is –O– or –O(CO)–, R 1 and R 2 Each independently is C 13-21 Alkyl, and R 3 The group is selected from hydrogen, C 1-10 Polyols, ethanolamine and serine, and salts thereof.

14. The contact lens of claim 1, wherein the packaging comprises: (a) a base member having a cavity for containing a packaging solution; and (b) A cover that forms a fluid-tight seal with the base member.

15. A method for making a hydrogel contact lens comprising a polymer lens body loaded with a glycerophospholipid, wherein the glycerophospholipid is a polymer lens body comprising a C 12 -C 26 Acyl glycerophospholipids, the method comprising: a) polymerizing a polymerizable composition in a contact lens casting mold to obtain the polymer lens body, b) removing the polymer lens body from the contact lens casting mold, c) placing the polymer lens body in a 12 -C 26 d) hydrating the polymer lens body in a hydrating liquid to obtain the hydrogel contact lens, e) sealing the hydrogel contact lens in a package with a packaging solution, and optionally, f) steam-treating the package.

16. A method for correcting vision in a symptomatic contact lens wearer, the method comprising: providing, by the symptomatic contact lens wearer, a contact lens comprising a load comprising C at the sn-2 position; 12 -C 26 A hydrogel contact lens having an acylglycerophospholipid polymer lens body.

17. The method of claim 16, wherein the symptomatic contact lens wearer has an increased duration of comfortable contact lens wear time compared to a control lens.

18. The method of claim 16, wherein the symptomatic contact lens wearer has reduced lens perception and / or fewer "lens perception events" during the day compared to a control lens.

19. A certain amount of a compound containing C at the sn-2 position 12 -C 26 Use of an acyl glycerophospholipid to enhance the comfort of a contact lens, wherein the phospholipid is associated with the polymer lens body of the contact lens.

20. The use according to claim 19, wherein the contact lens comprises a C 12 -C 26 A hydrogel contact lens having an acylglycerophospholipid polymer lens body.

21. The use according to claim 19, wherein the sensation perceived by the lens is reduced in the contact lens wearer, thereby enhancing the comfort of the contact lens in the symptomatic contact lens wearer and / or increasing the duration of comfortable contact lens wearing time in the symptomatic contact lens wearer.

22. A hydrogel composition for reducing lens perceived feel in a contact lens wearer, thereby enhancing the comfort of the contact lens in the contact lens wearer and / or increasing the duration of comfortable contact lens wearing time in the contact lens wearer, the composition comprising (a) a polymer lens body that is a reaction product of a polymerizable composition, the polymer lens body loading (b) an amount of a polyol comprising C at the sn-2 position; 12 -C 26 Acyl glycerophospholipids.

23. The composition for use according to claim 22, wherein the composition is in the form of a contact lens comprising a C 12 -C 26 Acylglycerophospholipid polymer lenses.

Citation Information

Patent Citations

  • Oleic acid-releasing contact lens

    US20220187620A1

  • Long wearable soft contact lens

    US6867245B2

  • Wettable silicone hydrogel contact lenses and related compositions and methods

    US8231218B2

  • Wettable silicone hydrogel contact lenses

    US8658747B2

  • Silicone hydrogel contact lenses

    US8865789B2